The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report
Siponimod (Kajendra) is a sphingosine-1-phosphate receptor modulator type 1 and 5 (S1P1,5), the first targeted agent for the treatment of patients with secondary progressive multiple sclerosis, both with and without exacerbations and/or activity according to magnetic resonance imaging. The drug was...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ZAO "Consilium Medicum"
2023-05-01
|
| Series: | Consilium Medicum |
| Subjects: | |
| Online Access: | https://consilium.orscience.ru/2075-1753/article/viewFile/553315/132684 |